Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Market Cap	31.67B
Revenue (ttm)	42.59M
Net Income (ttm)	-433.41M
Shares Out	168.46M
EPS (ttm)	-2.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	349,002
Average Volume	195,826
Open	184.50
Previous Close	182.00
Day's Range	178.00 - 188.00
52-Week Range	122.00 - 329.50
Beta	0.11
RSI	47.52
Earnings Date	Mar 10, 2026

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that is in Phase Ib/II clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and CS028, which is ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 43
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6535

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.